As of December 31, 2023, cash, cash equivalents and investments in marketable securities were $104.6M. “Tenaya had a successful year of sustained execution in 2023 that meaningfully advanced our portfolio of genetic medicines for heart disease. We announced IND clearance for the TN-201 and TN-401 gene therapy programs; activated clinical trial sites in the USA, Canada, and Europe; dosed the first patient with TN-201; manufactured sufficient clinical trial material for both gene therapy programs at our own cGMP facility; and presented compelling preclinical data from our gene editing and capsid engineering efforts,” said Faraz Ali, Chief Executive Officer of Tenaya. “We look forward to focusing efforts in 2024 on generating early clinical data with TN-201 from the MyPeak-1 study and on initiating patient dosing with TN-401 in the RIDGE-1 study.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TNYA:
- Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine
- TNYA Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
- Tenaya Therapeutics announces publication of preclinical HDAC6 inhibitor data
